Peptide Profile
ARA-290
Cibinetide · Innate Repair Receptor agonist
ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising…
- Half-life
- ~2 min (IV); ~10–20 min (SC)
- Routes
- subcutaneous, intravenous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What ARA-290 is
About ARA-290
Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing
ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.
ARA-290 Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
ARA-290 half-life calculator
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
What the evidence says about ARA-290
Research Evidence
based on 2 studies · 1 RCT · most recent 2026
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Investigational
Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 1 strong · 1 weak
1 RCT · 1 Animal
Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients
Investigative Ophthalmology & Visual Science · 2017
Research in a phase 2b randomized trial of 64 sarcoidosis patients with small nerve fiber loss found that cibinetide 4 mg significantly increased corneal nerve fiber area (p=0.012) and improvements correlated with functional gains on the 6-minute walk test, demonstrating nerve regenerative potential for this tissue-protective peptide.
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.
Neurobiol Dis · 2026
# Summary Research found that ARA-290 improved insulin sensitivity and altered immune cell profiles in diabetic mice, but did not restore impaired executive cognitive flexibility—the selective cognitive deficit observed in the Type 2 diabetes model. This study demonstrated that the cognitive dysfunction associated with diabetes involves chronic inflammation in brain regions like the hippocampus, and that peripheral metabolic improvement alone is insufficient to rescue executive function deficits.
ARA-290 Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
Reported (unverified — pending clinical review)
No established clinical contraindications
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSARA-290
Third-party testing data
Limited testing data (1 verified result)
We only show a verified-testing signal once at least 3 independent lab results are on file. Below that, we show what we have without implying a confidence signal.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Certificates of Analysis
- Checkable — no result recordedBlackline Scientific
ARA-290 10mg · Lot Clear Cap/Black Crimp · Aug 7, 2026 · View source COA
99.3%
Purity
- Confirmed by labJanoshik Analytical
ARA-290 · Jun 10, 2026 · View source COA
99.7%
Purity
- Checkable — no result recordedEZ Peptides
ARA-290 · Lot EZP-ARA1005192026-03 · Jun 3, 2026 · View source COA
99.8%
Purity
- Checkable — no result recordedAmeano Peptides
ARA-290 · Lot AMP-ARA1005192026-03 · Jun 3, 2026 · View source COA
99.8%
Purity
- Checkable — no result recordedRUO
ARA-290 · Lot ARA002 · May 6, 2026
- Confirmed by labModern Research Peptides
ARA 290 10mg · Lot LCHK262 · Feb 16, 2026 · View source COA
99.1%
Purity
PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Frequently Asked Questions — ARA-290
ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts.
neuropathic pain relief, tissue repair, anti-inflammatory, metabolic improvement.
Research on ARA-290 primarily documents effects related to neuropathic pain relief and tissue repair and anti-inflammatory and metabolic improvement. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for ARA-290 include active erythrocytosis. This is educational information only — consult a qualified healthcare professional before use.
For ARA-290, its FDA status is investigational (not FDA-approved), and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
15 providers in the directory currently offer ARA-290.
Across 34 research vendors tracked on PeptideBase, ARA-290 has a median price of about $4.95 per mg, typically ranging $3.91–$5.56 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
Research in a phase 2b randomized trial of 64 sarcoidosis patients with small nerve fiber loss found that cibinetide 4 mg significantly increased corneal nerve fiber area (p=0.012) and improvements correlated with functional gains on the 6-minute walk test, demonstrating nerve regenerative potential for this tissue-protective peptide.
How to get ARA-290
Market Pricing
34 vendorsPrice per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified August 2026 · ARA-290 price intelligence
Where to buy ARA-290
15 providersTelehealth Platforms
1 providerPhysicians
1 providerQuestions to ask your provider
Stay updated on ARA-290 providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). ARA-290 — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/ara-290